Status:
COMPLETED
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Lead Sponsor:
Kenya Medical Research Institute
Collaborating Sponsors:
University of Washington
Merck Sharp & Dohme LLC
Conditions:
HPV Vaccine
HPV Infection
Eligibility:
All Genders
9-14 years
Brief Summary
Longitudinal observational cohort study and extension of the MISP ID: 38406 'immunogenicity and safety of quadrivalent human papillomavirus vaccine in HIV-infected pre-adolescent girls and boys in Ken...
Detailed Description
We evaluated for persistence of HPV antibody by measuring titers to specific HPV types 6, 11, 16 and 18 at re-enrollment month 24 , 36 and 48 months in addition to month 7 and 12, after initial vaccin...
Eligibility Criteria
Inclusion
- receipt of 3 doses of QHPV vaccine
- participated in primary immunogenicity study
- consent/assent with parental consent for participants age \<18 years
- willing to continue extended follow up for 36 months
Exclusion
- decline consent
Key Trial Info
Start Date :
September 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2019
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT04711265
Start Date
September 1 2015
End Date
January 1 2019
Last Update
January 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Partners in Health Research and Development
Thika, Kiambu County, Kenya